In general, Andro and GA provide an alternative and complementary strategy for imatinib-resistant CML by inhibiting BCR-ABL function through a different mechanism than that of imatinib [59,60,61]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.